After the completion of the long-distance trial of the first Vande Bharat sleeper train, the Ministry of Railways has ordered ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the first ...

T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...

CARsgen’s first enrolled subject in the THANK-u Plus platform-based allogeneic CAR-T trial achieves sCR at week 4: Shanghai, China Tuesday, February 11, 2025, 18:00 Hrs [IST] CA ...

Laurie Adami's experience with CAR T-cell therapy highlights its potential in treating Non-Hodgkin Lymphoma, emphasizing the ...

Officials said that the full-scale production of the 24-car Vande Bharat Sleeper train may commence in 2026-27.

“Looking ahead, full-scale production of the 24-car Vande Bharat Sleeper Train sets will commence in 2026-27, further ...

New Delhi: The first 16-car Vande Bharat Sleeper Train Set, which successfully completed long distance trials on January 15 ...

Before the operationalisation of India’s first Vande Bharat sleeper train, the Research Designs & Standards Organisation (RDSO) will issue a final certificate after analysing the trial runs. The ...

For GM, the total is about one-third; for Ford, it's about a quarter. That's in addition to billions in imported components ...